Moore Capital Management LP Has $1.44 Million Stock Position in Replimune Group, Inc. $REPL

Moore Capital Management LP cut its stake in shares of Replimune Group, Inc. (NASDAQ:REPL) by 58.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 130,195 shares of the company’s stock after selling 180,929 shares during the quarter. Moore Capital Management LP’s holdings in Replimune Group were worth $1,441,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in Replimune Group in the 4th quarter valued at $29,000. CWM LLC lifted its holdings in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares in the last quarter. Allworth Financial LP bought a new stake in shares of Replimune Group in the second quarter valued at about $62,000. Essential Partners LLC boosted its position in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Down 1.3%

Shares of Replimune Group stock opened at $15.30 on Tuesday. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $16.15. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -4.86 and a beta of 0.88. The firm’s 50-day moving average price is $11.92 and its two-hundred day moving average price is $8.40.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, analysts forecast that Replimune Group, Inc. will post -2.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a report on Tuesday, June 30th. Finally, Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.00.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 9,256 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the sale, the chief financial officer directly owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the completion of the sale, the insider owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 79,124 shares of company stock worth $1,038,364. 5.40% of the stock is owned by company insiders.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.